During the last session, Adc Therapeutics SA (NYSE:ADCT)’s traded shares were 1.14 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $2.65, reflecting an intraday gain of 6.00% or $0.15. The 52-week high for the ADCT share is $4.13, that puts it down -55.85 from that peak though still a striking 60.38% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $262.83M, and the average trade volume was 427.93K shares over the past three months.
Adc Therapeutics SA (ADCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ADCT has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Adc Therapeutics SA (NYSE:ADCT) trade information
Adc Therapeutics SA (ADCT) registered a 6.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.00% in intraday trading to $2.65, hitting a weekly high. The stock’s 5-day price performance is 23.26%, and it has moved by 81.51% in 30 days. Based on these gigs, the overall price performance for the year is -27.20%.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 66.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $13 respectively. As a result, ADCT is trading at a discount of -390.57% off the target high and -164.15% off the low.
Adc Therapeutics SA (ADCT) estimates and forecasts
In the rating firms’ projections, revenue will increase 9.41% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.82M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 18.4M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 17.41M and 18.46M respectively. In this case, analysts expect current quarter sales to grow by 2.37% and then drop by -0.35% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.38%. While earnings are projected to return 1.44% in 2025, the next five years will return 15.31% per annum.
ADCT Dividends
Adc Therapeutics SA is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
The next largest institutional holding, with 9.57 million shares, is of PROSIGHT MANAGEMENT, LP’s that is approximately 10.0009% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $30.24 million.
Also, the Mutual Funds coming in first place with the largest holdings of Adc Therapeutics SA (ADCT) shares are iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund. Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Russell 2000 ETF owns about 2.06 shares. This amounts to just over 2.07 percent of the company’s overall shares, with a $5.45 million market value. The same data shows that the other fund manager holds slightly less at 815.1, or about 0.82% of the stock, which is worth about $2.16 million.
